1μg (R: reducing conditions, N: non-reducing conditions).
Biotinylated CEACAM-6/CD66c His&Avi Tag Protein, Human
Biotinylated CEACAM-6/CD66c His&Avi Tag Protein, Human
Price:
Regular price
$560.00 USD
Regular price
Sale price
$560.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | NCA |
| Accession | P40199-1 |
| Amino Acid Sequence | Lys35-Gly320, with C-terminal His&Avi tag KLTIESTPFNVAEGKEVLLLAHNLPQNRIGYSWYKGERVDGNSLIVGYVIGTQQATPGPAYSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVYPELPKPSISSNNSNPVEDKDAVAFTCEPEVQNTTYLWWVNGQSLPVSPRLQLSNGNMTLTLLSVKRNDAGSYECEIQNPASANRSDPVTLNVLYGPDVPTISPSKANYRPGENLNLSCHAASNPPAQYSWFINGTFQQSTQELFIPNITVNNSGSYMCQAHNSATGLNRTTVTMITVSGGGGSGGGSHHHHHHHHHHGLNDIFEAQKIEWHE |
| Expression System | HEK293 |
| Molecular Weight | 50-72kDa |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Biotin |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. Laura A Strickland,Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma,Journal of Pathology,J Pathol 2009; 218: 380-39. |
Background
CEACAM6 is a glycosylphosphoinosi-tol (GPI)-linked, cell surface protein and a member of the CEA family of proteins. Structurally, this protein has two C2-type Ig domains and a single N-terminal V-type Ig domain and shares close homology with CEACAM1, CEACAM7 and CEACAM8. Function-ally, CEACAM6 has been implicated in cell adhesion, cellular invasiveness, resistance to anoikis and metastatic behaviour of tumour cells, which are properties investigators have previously tried to exploit using various CEACAM6-targeted therapy approaches.
Picture
Picture
SDS-PAGE
